View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Robert Jan Vos ... (+2)
  • Robert Jan Vos
  • Usama Tariq
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Company comments AB InBev: Little to disappoint Adyen: 2H25 results – mixed results, soft guidance CVC Capital Partners: Executing well dsm-firmenich: Messy results Fagron: Beat on all lines, confident FY26 outlook to drive c.5% consensus EBITDA upgrade Flow Traders: EMEA saves the day KBC: Good results, opening up “jaws” further to 2028 Kinepolis: Canadian peer Cineplex 4Q25 results below consensus, January 2026 box office revenue up MICC: FX headwind leads to a 50bp margin miss in FY25 Montea:...

Hilde Van Boxstael ... (+8)
  • Hilde Van Boxstael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, ADYEN NA, DSFIR NA, FAGR BB, FLOW NA, NEXTA BB...

: ABI BB, ADYEN NA, DSFIR NA, FAGR BB, FLOW NA, NEXTA BB, MONT BB, NN NA, ONTEX BB, SIP BB, WDP BB, NXFIL NA

Thibault Leneeuw
  • Thibault Leneeuw

Fagron Solid FY25 Performance with Broad Based Momentum

Fagron delivered a solid FY25 performance, with revenue coming in 1% above CSS expectations, mainly supported by betterthanexpected growth in North America. REBITDA reached €193m, coming in 1.6% above CSS expectations, as all regions reported slightly higher margins than anticipated. Regionally, EMEA posted the strongest overall growth, driven by acquisitions, while North America and LatAm delivered DD organic growth at CER. For FY26, Fagron expects M to HSD organic growth at CER and a modest im...

 PRESS RELEASE

Fagron continues its outstanding performance in FY 2025 with 9.2% topl...

Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 February 2026 – 7AM CET Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA Fagron, the leading global player in pharmaceutical compounding, today publishes its full year results for the period ending 31 December 2025. Key Highlights Strong revenue growth with 9.2% reported growth (12.9% at CER1) to reach €952.2 million, ahead of guidance and supp...

 PRESS RELEASE

Fagron behoudt uitstekende prestaties in boekjaar 2025 met 9,2% omzetg...

Fagron behoudt uitstekende prestaties in boekjaar 2025 met 9,2% omzetgroei en een stijging van de REBITDA met 10,9% Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 12 februari 2026 – 7:00 AM CET Fagron behoudt uitstekende prestaties in boekjaar 2025 met 9,2% omzetgroei en een stijging van de REBITDA met 10,9% Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, publiceert vandaag haar jaarresultaten voor de periode eindigend op 31 december 2025. Belangrijkste hoogtepunten Sterke omzetgroei met een gerapporteerde stijging van 9,2% (12,9% tege...

 PRESS RELEASE

Galapagos Receives Transparency Notifications from Bank of America

Galapagos Receives Transparency Notifications from Bank of America Mechelen, Belgium; February 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications on February 5, 6, and 9, 2026, from Bank of America Corporation. The initial notification indicates that Bank of America Corporation, as controlling entity, crossed above the threshold of 5% of Galapagos’ voting rights on February 2, 2026, followed by its controlle...

 PRESS RELEASE

Galapagos ontvangt transparantieverklaringen van Bank of America  

Galapagos ontvangt transparantieverklaringen van Bank of America   Mechelen, België; 10 februari 2026, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft transparantieverklaringen ontvangen van Bank of America. Overeenkomstig de Belgische transparantiewetgeving1 ontving Galapagos op 5, 6 en 9 februari 2026 transparantieverklaringen van Bank of America Corporation. Daaruit blijkt dat Bank of America Corporation, als controlerende entiteit, op 2 februari 2026 de drempel van 5% van de stemrechten van Galapagos heeft overschreden, gevolgd door haar gecontro...

Stijn Demeester
  • Stijn Demeester

Fagron/Compounding organic growth and accretive M&A/BUY

We raise our target price for Fagron from €25.5 to €27.0 ahead of its FY25 results on 12 February. We reiterate our BUY recommendation as the shares continue to offer a compelling combination of organic growth (2018-25F CAGR 8%, 2025-30F target HSD% to LDD%) and active and accretive M&A, in our view.

Guy Sips ... (+3)
  • Guy Sips
  • Hilde Van Boxstael
  • Wim Lewi
Guy Sips
  • Guy Sips

X Fab Silicon Foundries EV FIRST LOOK : Cautious on near term given on...

We updated our model as 1Q26 revenue is expected to come in within the range of $190-200m (KBCS from the low of the markets ($200.6m while CSS was $ 213.4m) to $ 195m now with an EBITDA margin in the range of 18% and 21% (KBCSe new 21.2%). We regret X-FAB is not providing FY26 guidance at this time due to limited visibility and the current macroeconomic environment. We think CSS will have to lower FY26E forecast substantially (CSS was $ 916.6m sales and 26.3% EBITDA-margin) and as a result we lo...

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Mathijs Geerts Danau
  • Wim Lewi
 PRESS RELEASE

Fagron obtains regulatory clearance for the acquisition of Vepakum in ...

Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 5 February 2026 Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary Additionally, the completion of Vepakum is expected to take place shortly. Following these milestones, Injeplast and Amber remain subject to closing, together with Vepakum. Vepakum Vepakum operates two facilities in São Paulo, ...

 PRESS RELEASE

Fagron verkrijgt goedkeuring van lokale autoriteiten voor de overname ...

Fagron verkrijgt goedkeuring van lokale autoriteiten voor de overname van Vepakum in Brazilië en rondt de overname van Magilab in Hongarije af Gereglementeerde informatie - voorwetenschapNazareth (België)/Rotterdam (Nederland), 5 februari 2026 – 7:00 AM CET Fagron verkrijgt goedkeuring van lokale autoriteiten voor de overname van Vepakum in Brazilië en rondt de overname van Magilab in Hongarije af Daarnaast wordt verwacht dat de overname van Vepakum op korte termijn zal worden afgerond. Na deze mijlpalen blijven Injeplast en Amber, samen met Vepakum, onderhevig aan afronding. Vepakum V...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch